arrow
F

Felix Luessi

johannes gutenberg university of mainz
H指数:35
被引数:6,684

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cellular and humoral vaccination response under immunotherapies—German consensus on vaccination strategies in neurological autoimmune diseases

细胞和体液疫苗接种反应在免疫疗法下——德国关于神经自身免疫性疾病疫苗接种策略的共识

2025-12-120
OA
Genetic Risk Variants for Multiple Sclerosis and Other Loci Linked to Intrathecal Immunoglobulin G Synthesis

多发性硬化症的遗传风险变异和与鞘内免疫球蛋白G合成相关的其他基因座

2025-11-010
PRE
Dyadic Coping of NMOSD and MOGAD patients and their partners: a sociological and psychological examination of strategies (CoMMOnsense-Study)

视神经脊髓炎谱系障碍(NMOSD)和MOG抗体介导的中枢神经系统脱髓鞘疾病(MOGAD)患者及其伴侣的二元应对:一项关于策略的社会学和心理学考察(CoMMOnsense研究)

2025-10-020
OAAI
HLA-A∗03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis

HLA-A∗03:01作为预测干扰素β治疗反应的遗传生物标志物在多发性硬化中的研究:一项回顾性队列分析

2025-07-310
PRE
Multiple sclerosis endophenotypes identified by high-dimensional blood signatures are associated with distinct disease trajectories

通过高维血液特征识别的多发性硬化症内表型与不同的疾病轨迹相关

2024-03-274
PRE
B cell depletion with anti-CD20 promotes neuroprotection in a BAFF-dependent manner in mice and humans
2024-03-064
PRE
Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases COPANMO(G)-Study
2023-03-017
OAAI
Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study)
2023-02-1410
OAAI
Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis

继发性进行性多发性硬化症患者使用siponimod治疗的真实世界证据

2022-11-078
OAAI
Association of obesity with disease outcome in multiple sclerosis

肥胖与多发性硬化症疾病结局的关系

2022-11-0142
OAAI